Biomolecular Life Holdings, Inc.

AI-generated fair value estimate for this company.

Method: NAV from the Sept 29, 2026 Form 10-12G/A: total liabilities of ~$1.54M (related-party/demand obligations) against $0 cash and one small unencumbered Miami warehouse condo as the only material asset, over 51,161,595 shares outstanding (147,019,877 fully diluted); net asset value is negative, so the estimate is held near-zero rather than a hard $0.00 only to reflect residual option value in the new 15%-of-net-revenue marketing agreement with Biomolecular Life LLC, which just began generating ~$5,000/quarter in mid-2026.

Reasoning: BIOM only exited shell status on July 23, 2026 and has essentially no revenue history, negative equity, and a going-concern opinion, so a DCF would be fabricated; book value is the only grounded method available and it comes out negative/near-zero, far below any speculative quoted price.